Real-World Experience With Mavacamten in SRT-Eligible Obstructive HCM
JACC Adv. 2026 Jul 1;5(8):102956. doi: 10.1016/j.jacadv.2026.102956. Online ahead of print.ABSTRACTBACKGROUND: Mavacamten, a cardiac myosin inhibitor, has been shown to improve symptoms and reduce left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy (oHCM). However, re

